Diabetes News February 24th 2012

Study finds some insulin production in long-term type 1 diabetes
C-peptide production and beta cell functioning detected decades after disease onset (Massachusetts General Hospital)

Acute Response of Peripheral Blood Cell to Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetic Patient
Despite the small patient number and prospective study design, we believe our findings provide important insights for understanding AHST effectiveness and possible molecular clues for optimizing AHST management in T1D patients (PLoS ONE)

Integrating an Automated Diabetes Management System Into the Family Management of Children With Type 1 Diabetes
Using the ADMS 1–3 times/week may help children with type 1 diabetes improve glycemic control and gain diabetes self-management skills, as well as improve the BGM effect of parents (Diabetes Care)

CK-elevation, lactacidosis and metabolic myopathy in adult patients with diabetes
Hyper-CK-emia occurs in one fifth and lactacidosis in one quarter of the patients with diabetes. Hyper-CK-emia in these patients is attributable to a primary metabolic myopathy in most of the cases. Hyper-CK-emia in patients with diabetes requires further neurological diagnostic work-up (Endocrine Practice)

Clinical Utility of Creatinine- and Cystatin C-Based Definition of Renal Function for Risk Prediction of Primary Cardiovascular Events in Patients With Diabetes
Only the cystatin C-based CKD definition was an independent risk predictor for cardiovascular events in our diabetic study cohort and indicated a potentially better clinical utility for cardiovascular risk prediction than creatinine-based equations (Diabetes Care)

Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes
Compared with patients whose prevalent diabetes is managed outside of primary care networks, patients in primary care networks had a lower rate of diabetes-specific ambulatory care sensitive conditions, were more likely to see an ophthalmologist or optometrist and had better glycemic control (Canadian Medical Journal)

The Risk of a Persistent Glucose Metabolism Impairment After Gestational Diabetes Mellitus Is Increased in Patients With Polycystic Ovary Syndrome
Patients with PCOS are at increased risk for a persistent impaired glucose metabolism after GDM (Diabetes Care)

Hypertensive Disorders in Pregnancy and Subsequent Diabetes Mellitus: A Retrospective Cohort Study
HDP women with obesity and hyperlipidemia are at an extremely high risk of diabetes mellitus. Early identification of women with HDP is needed for prevention, particularly those with other comorbidities (American Journal of Medicine)

Associations of maternal A1C and glucose with pregnancy outcomes
On the basis of associations with adverse outcomes, these findings suggest that A1C measurement is not a useful alternative to an OGTT in pregnant women (Diabetes Care)

Elevated Amylase and Lipase in Patients Using GLP-1 Receptor Agonists or DPP-4 Inhibitors in the Outpatient Setting
Both GLP-1 agonists and DPP-4 inhibitors are associated with increased serum lipase more than serum amylase in many patients with type 2 diabetes possibly suggesting pancreatic inflammation. Whether this may potentially lead to acute pancreatitis or chronic pancreatitis as reported in rat models remains a question. Careful observation of patients taking these medications may be required. (Endocrine Practice)

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes
Prolonged-release exenatide in triple therapy regimens (that is, in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as a treatment option for people with type 2 diabetes as described in ‘Type 2 diabetes: the management of type 2 diabetes‘ (NICE)

CHMP Recommends Approval of BYETTA® for Use With Basal Insulin
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion in the European Union (EU) for the expanded use of BYETTA® (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents (Lilly)